1. Academic Validation
  2. Measuring Histone Deacetylase Inhibition in the Brain

Measuring Histone Deacetylase Inhibition in the Brain

  • Curr Protoc Pharmacol. 2018 Jun;81(1):e41. doi: 10.1002/cpph.41.
Doodipala Samba Reddy 1 Xin Wu 1 Victoria M Golub 1 W Mohaiza Dashwood 2 Roderick H Dashwood 2
Affiliations

Affiliations

  • 1 Department of Neuroscience and Experimental Therapeutics, Texas A&M University Health Science Center, College of Medicine, Bryan, Texas.
  • 2 Center for Epigenetics & Disease Prevention, Texas A&M University Health Science Center, College of Medicine, Houston, Texas.
Abstract

Histone deacetylases (HDACs) represent a family of enzymes that are targets for epigenetic modulation of genomic activity and may be beneficial in the treatment of many diseases, including Cancer and central nervous system disorders. In animal models, HDAC inhibitors have neuroprotective, antiepileptogenic, and antidepressant effects. Assaying HDAC activity provides a robust method for identifying HDAC inhibitors and for assessing their effects under various physiological conditions or after pathological insults. In this unit, a simple and sensitive assay for measuring HDAC activity is described. HDAC activity in tissue lysates can be assessed fluorometrically using a Boc-Lys(Ac) HDAC activity kit. HDACs catalyze the deacetylation of the substrate Boc-Lys(Ac)-AMC. Addition of a trypsin-containing developer converts the deacetylated product to a quantifiable fluorophore that can be used both as a screening method to identify putative HDAC inhibitors and to assess the effects of these inhibitors on tissue and animal epigenetic-modulated phenotypes. © 2018 by John Wiley & Sons, Inc.

Keywords

HDAC; HDAC substrate; epigenetic; fluorophore; nuclear protein; sodium butyrate; trichostatin A.

Figures
Products